Imunon, Inc.

NasdaqCM:IMNN Stock Report

Market Cap: US$9.7m

Imunon Management

Management criteria checks 1/4

Imunon's CEO is Stacy Lindborg, appointed in May 2024, has a tenure of 1.58 years. total yearly compensation is $1.38M, comprised of 23.7% salary and 76.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $12.03K. The average tenure of the management team and the board of directors is 1.4 years and 7.4 years respectively.

Key information

Stacy Lindborg

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage23.74%
CEO tenure1.6yrs
CEO ownership0.1%
Management average tenure1.4yrs
Board average tenure7.4yrs

Recent management updates

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Celsion Q2 2022 Earnings Preview

Aug 12

Celsion adds Moderna chief commercial officer as CEO

Jul 19

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Dec 07
Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

CEO Compensation Analysis

How has Stacy Lindborg's remuneration changed compared to Imunon's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$16m

Mar 31 2025n/an/a

-US$18m

Dec 31 2024US$1mUS$327k

-US$19m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$44kn/a

-US$20m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$55kn/a

-US$36m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$26m

Mar 31 2022n/an/a

-US$26m

Dec 31 2021US$63kn/a

-US$21m

Compensation vs Market: Stacy's total compensation ($USD1.38M) is above average for companies of similar size in the US market ($USD576.00K).

Compensation vs Earnings: Stacy's compensation has increased whilst the company is unprofitable.

CEO

Stacy Lindborg (54 yo)

1.6yrs
Tenure
US$1,377,759
Compensation

Dr. Stacy R. Lindborg, Ph D., was Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since January 2023 until May 09, 2024 and serves as its Director since May 09, 2024. Dr. Lindborg joined th...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Tardugno
Executive Chairman18.9yrsUS$734.81k0.18%
$ 17.8k
Stacy Lindborg
President1.6yrsUS$1.38m0.12%
$ 12.0k
Khursheed Anwer
Executive VP & Chief Scientific Officer11.5yrsUS$741.68k0.11%
$ 10.8k
Kimberly Graper
CFO and Principal Financial & Accounting Officerless than a yearno datano data
Timothy Tumminello
Chief Accounting Officer & Controller15.9yrsUS$137.75kno data
Susan Eylward
General Counsel & Corporate Secretary1.2yrsno data0%
$ 0
Kristin Longobardi
Senior Vice President of Strategic Operations1.2yrsno datano data
Douglas Faller
Chief Medical Officerless than a yearno datano data
1.4yrs
Average Tenure
66yo
Average Age

Experienced Management: IMNN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Michael Tardugno
Executive Chairman18.9yrsUS$734.81k0.18%
$ 17.8k
Stacy Lindborg
President4.5yrsUS$1.38m0.12%
$ 12.0k
Donald Braun
Independent Director10yrsUS$71.60k0.14%
$ 13.6k
Wafik El-Deiry
Member of Advisory Boardno datano datano data
David Cheresh
Member of Advisory Boardno datano datano data
Michael Weinblatt
Member of Advisory Boardno datano datano data
James Dentzer
Independent Director3.3yrsUS$63.98k0.12%
$ 12.0k
Frederick Fritz
Independent Director14.4yrsUS$106.73k0.15%
$ 14.3k
Jerry Glickson
Member of Advisory Boardno datano datano data
Mark Dewhirst
Member of Advisory Boardno datano datano data
Peter Corry
Member of Advisory Boardno datano datano data
Britt Glaunsinger
Member of the Advisory Board4.8yrsno datano data
7.4yrs
Average Tenure
74yo
Average Age

Experienced Board: IMNN's board of directors are considered experienced (7.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/28 02:55
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imunon, Inc. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets